Insights › Medicine & pharma › November 19, 2026
Medicine & pharma · Pipeline & development

Interlude Biopharma Launches at the International Celiac Disease Symposium and Announces Prevention-Focused Phase 3 Clinical Trial

PR Newswire (Health) Published: Trial

First Celiac Prevention Study Expected to Start in First Quarter of 2027 MIAMI and MELBOURNE, Australia, Nov. 19, 2026 /PRNewswire/ -- Mark Paresky, co-founder and executive chairman of Interlude Biopharma Co., today announced the company's public launch at the 21st International Celiac...

Original source
Read the source — prnewswire.com ↗

We link to the original publisher. The summary above is a short guide; read the original for the full details.

More in Medicine & pharma

See everything in Medicine & pharma →

Look into this further

Read every record in your own language

This page shows the three newest items per field. Members see every record in the field, in 109 languages, with the search engines that work on them.

Read it all — start from $3No app-store installation. Cancel any time.